MEDP - Medpace Holdings
Earnings Results

Medpace Holdings ( $MEDP )

Recent earnings result

  1. Medpace EPS beats by $0.28, beats on revenue

Events & Presentations

Q2 2020 Medpace Holdings, Inc. Earnings Conference Call

Supporting docs

  1. Listen to webcast
  2. PDF document

Top Stories (MEDP)

Events & Annual meetings

Title Date Webcast
Q2 2020 Medpace Holdings, Inc. Earnings Conference Call July 28, 2020 at 9:00 AM EDT google.com webcast
investor.medpace.com PDF
Q1 2020 Medpace Holdings, Inc. Earnings Conference Call April 29, 2020 at 9:00 AM EDT
investor.medpace.com PDF
Q4 2019 Medpace Holdings, Inc. Earnings Conference Call February 25, 2020 at 9:00 AM EST
investor.medpace.com PDF
Q3 2019 Medpace Holdings, Inc. Earnings Conference Call October 29, 2019 at 9:00 AM EDT
investor.medpace.com PDF
Q2 2019 Medpace Holdings, Inc. Earnings Conference Call July 30, 2019 at 9:00 AM EDT
investor.medpace.com PDF





Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,400 people across 38 countries as of June 30, 2020.


Disclaimer:

The Content is made available for informational purposes only. The Content may not be complete and may be subject to change.
The Content is provided without any warranty of any kind, either express or implied.
We have collected the events here to help investors easily find the informations they need.
These are manually collected by our researchers directly from Official IR pages and not third party sources.

Recent results

Books we are reading